Blog
RSS FeedPosted by Michael Wonder on 25 Aug 2024
Lupin receives Health Canada approval for biosimilar pegfilgrastim
23 August 2024 - Lupin today announced that it has received approval from Health Canada for its biosimilar Pegfilgrastim. ...
Posted by Michael Wonder on 16 Aug 2024
First public drug plans provide reimbursement for Camzyos for adults with symptomatic obstructive hypertrophic cardiomyopathy
15 August 2024 - BMS Canada is pleased to announce an important milestone for eligible patients with symptomatic obstructive hypertrophic ...
Posted by Michael Wonder on 15 Aug 2024
Imfinzi granted priority review and breakthrough therapy designation for patients with limited-stage small cell lung cancer in the US
15 August 2024 - Based on ADRIATIC Phase 3 trial which demonstrated statistically significant and clinically meaningful overall survival and ...
Posted by Michael Wonder on 13 Aug 2024
Introducing Jubbonti and Wyost, the first denosumab biosimilars on the Canadian market
12 August 2024 - Jubbonti and Wyost are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access ...
Posted by Michael Wonder on 09 Aug 2024
Canada’s Drug Agency taking steps to expand access to real world evidence
7 August 2024 - Canada’s Drug Agency has published a summary report from its time-limited Industry Task Force. ...
Posted by Michael Wonder on 04 Aug 2024
First time-limited reimbursement recommendation supports earlier patient access to a promising cancer treatment
30 July 2024 - Patients in Canada with advanced-stage lymphoma are one step closer to accessing the first drug to receive ...
Posted by Michael Wonder on 02 Aug 2024
Marius Pharmaceuticals submits Kyzatrex (testosterone undecanoate) capsules for approval to Health Canada
30 July 2024 - Marius Pharmaceuticals is pleased to announce the submission of its new drug submission for Kyzatrex (testosterone ...
Posted by Michael Wonder on 02 Aug 2024
Nordimet (methotrexate) self-injection pen now available in Canada for treatment of rheumatoid arthritis and psoriasis/psoriatic arthritis
1 August 2024 - Linepharma is pleased to announce that Nordimet (methotrexate), the first methotrexate single-use pre-filled pen for self-injection, ...
Posted by Michael Wonder on 02 Aug 2024
Health Canada approves Celltrion’s Steqeyma, a biosimilar to Stelara (ustekinumab) for the treatment of multiple chronic inflammatory conditions
1 August 2024 - Steqeyma, is now approved in Canada for adult patients with plaque psoriasis as well as adults with ...
Posted by Michael Wonder on 30 Jul 2024
HLS announces reimbursement for Vascepa under Alberta's Provincial Drug Plan
29 July 2024 - With the addition of Alberta's public plan, Vascepa will be available to more than 90% of ...
Posted by Michael Wonder on 30 Jul 2024
Health Canada authorizes Vabysmo (faricimab injection) for the treatment of macular oedema secondary to retinal vein occlusion
29 July 2024 - This is the third indication for Vabysmo, in addition to neovascular or 'wet' age-related macular degeneration and ...
Posted by Michael Wonder on 27 Jul 2024
Vertex announces FDA acceptance of new drug application for vanzacaftor/tezacaftor/deutivacaftor, a next in class triple combination treatment for cystic fibrosis
2 July 2024 - Vanza triple granted priority review with a PDUFA target action date of 2 January 2025. ...
Posted by Michael Wonder on 25 Jul 2024
Kye Pharmaceuticals secures exclusive license, supply and commercialisation agreement with Catalyst Pharmaceuticals for Agamree, a novel treatment for Duchenne muscular dystrophy, in Canada
24 July 2024 - Kye Pharmaceuticals today announced that it has entered into a license, supply and commercialisation agreement with Catalyst ...
Posted by Michael Wonder on 25 Jul 2024
Health Canada grants full approval to Jemperli for the treatment of patients with recurrent or advanced dMMR/MSI-H endometrial cancer
24 July 2024 - The conversion of this indication from Notice of Compliance to full approval is based on long term ...
Posted by Michael Wonder on 24 Jul 2024
Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia due to extravascular haemolysis
23 July 2024 - ALPHA Phase 3 trial showed first in class, oral, factor D inhibitor as add-on to Ultomiris ...